These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23920427)

  • 21. High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients.
    Wang JL; Lai CH; Lin HH; Chen WF; Shih YC; Hung CH
    Int J Antimicrob Agents; 2013 Nov; 42(5):390-4. PubMed ID: 24041465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Activity of vancomycin, teicoplanin and linezolid in methicillin resistant coagulase-negative Staphylococci isolates from paediatric blood cultures].
    Fajardo Olivares M; Hidalgo Orozco R; Rodríguez Garrido S; Gaona Álvarez C; Sánchez Silos RM; Hernández Rastrollo R; Martínez Tallo E; Cordero Carrasco JL
    Rev Esp Quimioter; 2012 Mar; 25(1):25-30. PubMed ID: 22488538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is vancomycin MIC "creep" method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010.
    Edwards B; Milne K; Lawes T; Cook I; Robb A; Gould IM
    J Clin Microbiol; 2012 Feb; 50(2):318-25. PubMed ID: 22135252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activities of ceftobiprole, dalbavancin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus blood isolates: stratified analysis by vancomycin MIC.
    Chong YP; Park SJ; Kim HS; Kim ES; Kim MN; Kim SH; Lee SO; Choi SH; Jeong JY; Woo JH; Kim YS
    Diagn Microbiol Infect Dis; 2012 Jul; 73(3):264-6. PubMed ID: 22621914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences in vancomycin minimum inhibitory concentrations for Staphylococcus aureus obtained with the automated Phoenix™ system, the Clinical and Laboratory Standards Institute broth microdilution method and the standard Etest.
    Muñoz-Cobo B; Sancho-Tello S; Costa E; Bravo D; Torregrosa I; de Lomas JG; Navarro D
    Int J Antimicrob Agents; 2011 Mar; 37(3):278-9. PubMed ID: 21269809
    [No Abstract]   [Full Text] [Related]  

  • 26. Use of Monte Carlo simulation to evaluate the development of vancomycin resistance in meticillin-resistant Staphylococcus aureus.
    Mei Q; Ye Y; Zhu YL; Cheng J; Yang HF; Liu YY; Li HR; Li JB
    Int J Antimicrob Agents; 2015 Jun; 45(6):652-6. PubMed ID: 25813394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?
    Lodise TP; Drusano GL; Zasowski E; Dihmess A; Lazariu V; Cosler L; McNutt LA
    Clin Infect Dis; 2014 Sep; 59(5):666-75. PubMed ID: 24867791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced susceptibility to vancomycin in methicillin resistant staphylococcus aureus: a time for action.
    Amatya R; Devkota P; Gautam A
    Nepal Med Coll J; 2014 Sep; 16(1):42-4. PubMed ID: 25799810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
    Steinkraus G; White R; Friedrich L
    J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vancomycin MICs of the resistant mutants of S. aureus ATCC43300 vary based on the susceptibility test methods used.
    Zhu YL; Mei Q; Hu LF; Cheng J; Ye Y; Li JB
    J Antibiot (Tokyo); 2012 Jun; 65(6):307-10. PubMed ID: 22491134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC = 2 mg/L, by the broth microdilution method.
    Wang JL; Wang JT; Sheng WH; Chen YC; Chang SC
    BMC Infect Dis; 2010 Jun; 10():159. PubMed ID: 20529302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong.
    Ho PL; Lo PY; Chow KH; Lau EH; Lai EL; Cheng VC; Kao RY
    J Infect; 2010 Feb; 60(2):140-5. PubMed ID: 19961873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantifying the matrix of relationships between reduced vancomycin susceptibility phenotypes and outcomes among patients with MRSA bloodstream infections treated with vancomycin .
    Lodise TP; Drusano GL; Lazariu V; El-Fawal N; Evans A; Graffunder E; Stellrecht K; Mendes RE; Jones RN; Cosler L; McNutt LA
    J Antimicrob Chemother; 2014 Sep; 69(9):2547-55. PubMed ID: 24840624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different formulations of vancomycin: In vitro antimicrobial activity against clinical isolates of methicillin-resistant Staphylococcus aureus.
    Fabri FV; Lolis MA; Gimenes M; Tognim MCB; Caparroz-Assef SM
    Diagn Microbiol Infect Dis; 2018 Dec; 92(4):332-337. PubMed ID: 30033164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of the MBC/MIC ratio on the antibacterial activity of vancomycin versus linezolid against methicillin-resistant Staphylococcus aureus isolates in a pharmacodynamic model simulating serum and soft tissue interstitial fluid concentrations reported in diabetic patients.
    Gonzalez N; Sevillano D; Alou L; Cafini F; Gimenez MJ; Gomez-Lus ML; Prieto J; Aguilar L
    J Antimicrob Chemother; 2013 Oct; 68(10):2291-5. PubMed ID: 23674766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of increase in vancomycin resistance of pediatric methicillin-resistant Staphylococcus aureus Isolates from 2000 to 2007.
    Zheng X; Qi C; Arrieta M; O'Leary A; Wang D; Shulman ST
    Pediatr Infect Dis J; 2010 Sep; 29(9):882-4. PubMed ID: 20453708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates.
    Pitz AM; Yu F; Hermsen ED; Rupp ME; Fey PD; Olsen KM
    J Clin Microbiol; 2011 Jan; 49(1):269-74. PubMed ID: 20962147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of vancomycin and daptomycin MICs by different testing methods for methicillin-resistant Staphylococcus aureus.
    Kruzel MC; Lewis CT; Welsh KJ; Lewis EM; Dundas NE; Mohr JF; Armitige LY; Wanger A
    J Clin Microbiol; 2011 Jun; 49(6):2272-3. PubMed ID: 21450951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Etest versus vitek 2 vancomycin minimum inhibitory concentration testing methods for methicillin-resistant staphylococcus aureus: an antimicrobial stewardship initiative to evaluate the degree of discordance among methods at a rural tertiary hospital.
    Bloomgren BJ; Laible BR
    J Pharm Pract; 2013 Aug; 26(4):415-9. PubMed ID: 23907075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glycopeptide minimum inhibitory concentration creep among meticillin-resistant Staphylococcus aureus from 2006-2011 in China.
    Zhuo C; Xu YC; Xiao SN; Zhang GY; Zhong NS
    Int J Antimicrob Agents; 2013 Jun; 41(6):578-81. PubMed ID: 23562222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.